uniQure N.V. Ordinary Shares vs Rubrik Inc. Class A Common Stock — how do they compare? uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B), while Rubrik Inc. Class A Common Stock trades at $112.37 (market cap $24.56B). The key difference: Rubrik Inc. Class A Common Stock is far larger — about 16.6× uniQure N.V. Ordinary Shares's market cap, and Rubrik Inc. Class A Common Stock is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and Rubrik Inc. Class A Common Stock for 4 Days on average.
| QURE | RBRK | |
|---|---|---|
Market Cap | $1.48B | $24.56B |
Volume | 2,488,780 | 2,289,465 |
Sector | Health | Technology |
52-Week High | $70.59 | $125.80 |
52-Week Low | $9.03 | $43.81 |
Typical Hold Time | 0 Days | 4 Days |
Enterprise Value | $728.62M | $23.96B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Rubrik (RBRK) trades at $118.47, down 1.28% on the day, with strong technical momentum showing bullish moving averages and support at $118. The company demonstrates impressive revenue growth, with 2026 revenue reaching $1.5B and recent earnings beats, though profitability remains negative with a -16.5% net margin. Recent news highlights expansion of AI security offerings including Rubrik Code Guardian and strong institutional buying interest.
Rubrik presents a compelling growth story in cybersecurity with 100% analyst buy ratings and $105.08 consensus target, though current price exceeds this. Key risks include persistent losses despite revenue growth and competitive AI security landscape. The stock's technical strength and AI-driven demand create upside potential, but profitability concerns warrant careful monitoring of margin improvement.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →Rubrik provides data security and cyber recovery software for enterprises. Its platform protects data across on-premises, cloud, SaaS, and unstructured-data environments.
Read more on RBRK →